Relevance of the vascular effects of insulin in the rationale of its therapeutical use

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 4, 2007, Pages 228-249

  Anfossi, Giovanni ^a   Russo, Isabella ^a   Doronzo, Gabriella ^a   Trovati, Mariella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Endothelial cells; Endothelin 1; Insulin; Insulin resistance; Platelets; Vascular smooth muscle cells

Indexed keywords

ENDOTHELIN 1; GLUCOSE; INSULIN; NITRIC OXIDE; POTASSIUM;

ALGORITHM; ANGIOGENESIS; BLOOD GLUCOSE MONITORING; BLOOD VESSEL TONE; CARBOHYDRATE METABOLISM; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; ENDOTHELIUM; HEART INFARCTION; HEMOSTASIS; HUMAN; INFLAMMATION; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; SYMPATHETIC TONE; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION;

EID: 37349058207     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907782793581     Document Type: Review

References (294)

1. Baron, A.D. Hemodynamic actions of insulin. Am. J. Physiol., 1994, 267, E187-E202.
2. Baron, A.D.; Brechtel, G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Influence of insulin sensitivity. Am. J. Physiol., 1993, 265, E61-E67.
3. Hajek, A.S.; Joist, J.H.; Baker, R.K.; Jarett, L.; Daughaday, W.H. Demonstration and partial characterization of insulin receptors in human platelets. J. Clin. Invest., 1979, 63, 1060-1065.
4. Falcon, C.; Pfliegler, G.; Deckmyn, H.; Vermylen, J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem. Biophys. Res. Commun., 1988, 157, 1190-1196.
5. Bar, R.S.; Hoak, J.C.; Peacock, M.L. Insulin receptors in human endothelial cells: identification and characterization. J. Clin. Endocrinol. Metab., 1978, 47, 699-702.
6. King, G.L.; Buzney, S.M.; Kahn, C.R.; Hetu, N.; Buchwald, S.; Macdonald, S.G.; Rand, L.I. Differential responsiveness to insulin of endothelial and support cells from micro and macrovessels. J. Clin. Invest., 1983, 71, 974-979.
7. Saltiel, A.R., Kahn, C.R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature, 2001, 414, 799-806.
8. Sesti, G.; Federici, M.; Lauro, D.; Sbraccia, P.; Lauro, R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of insulin receptor variant forms. Diabetes Metab. Res. Rev., 2001, 17, 363-373.
9. Pessin, J.E.; Saltiel, A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest., 2000, 106, 165-169.
10. Taniguchi, C.M.; Emanuelli, B.; Kahn, C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell. Biol., 2006, 7, 85-96.
11. Elchebly, M.; Payette, P.; Michaliazyn, E.; Cromlish, W.; Collins, S.; Loy, A.L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C.C.; Ramachandran, C.; Gresser, M.J.; Tremblay, M.L.; Kennedy, B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase1B gene. Science, 1999, 283, 544-548.
12. Stumvoll, M.; Goldstein, B.J.; van Haeften, T. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005, 365, 1333-1346.
13. White, M.F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem., 1998, 182, 3-11.
14. Araújo, E.P.; De Souza, C.T.; Gasparetti, A.L.; Ueno, M.; Boschero, A.C.; Saad, M.J.A.; Velloso, L.A. Short term in vivo inhibition of insulin receptor substrate-1 leads to insulin resistance, hyperinsulinemia, and increased adiposity. Endocrinology, 2005, 146, 1428-1437.
15. Banfi, C.; Eriksson, P.; Giandomenico, G.; Mussoni, L.; Sironi, L.; Hamste, A.; Tremoli, E. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes, 2001, 50, 1522-1530.
16. Moncada, S.; Higgs, E.A. Nitric oxide and the vascular endothelium. Handb. Exp. Pharmacol., 2006, 176 (Pt 1), 213-254.
17. Moncada, S.; Higgs, E.A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol., 2006, 147, S193-S201.
18. Jiang, Z.Y.; He, Z.; King B.L.; Kuroki, T.; Opland, D.M.; Suzuma, K.; Suzuma, I.; Ueki, K.; Kulkarni, R.N.; Kahn, C.R.; King, G.L. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J. Biol. Chem., 2003, 278, 31964-31971.
19. Doronzo, G.; Russo, I.; Mattiello, L.; Anfossi, G.; Bosia, A.; Trovati, M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur. J. Clin. Invest., 2004, 34, 664-673.
20. Doronzo, G.; Russo, I.; Mattiello, L.; Riganti, C.; Anfossi, G.; Trovati. M. Insulin activates hypoxia-inducible factor-1alpha in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia, 2006, 49, 1049-1063.
21. Wang, C.C.; Goalstone, M.L.; Draznin, B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes, 2004, 53, 2735-2740.
22. Groop, P-H.; Forsblom, C.; Thomas, M.C. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat. Clin. Pract. Endocrinol. Metab., 2005, 1, 100-110.
23. Jiang, Z.Y.; Lin, Y-W.; Clemont, A.; Feener, E.P.; Hein, K.D.; Igarashi, M.; Yamauchi, T.; White, M.F.; King, G.L. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker fa/fa rats. J. Clin. Invest., 1999, 104, 447-457.
24. Carvalheira, J.B.C.; Calegari, V.C.; Zecchin, H.G.; Nadruz, W.; Guimarães, R.B.; Ribeiro, E.B.; Franchini, K.G.; Velloso, L.A.; Saad, M.J.A. The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology, 2003, 144, 5604-5614.
25. Cusi, K.; Maezono, K.; Osman, A.; Pendergrass, M.; Patti, M.E.; Pratipanawatr, T.; DeFronzo, R.A.; Kahn, C.R.; Mandarino, L.J. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest., 2000, 105, 311-320.
26. Pandolfi, A.; Solini, A.; Pellegrini, G.; Mincione,. G, Di Silvestre, S.; Chiozzi, P.; Giardinelli, A.; Di Marcantonio, M.C.; Piccirelli, A.; Capani, F.; Consoli, A. Selective insulin resistance affecting nitric oxide release but not Plasminogem Activator Inhibitor-1 synthesis in fibroblasts from insulin-risistant individuals. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2392-2397.
27. Osman, A.A.; Hancock, J.; Hunt, D.G.; Ivy, J.L.; Mandarino, L.J. Exercise training increases ERK2 activity in skeletal muscle of obese Zucker rats. J. Appl. Physiol., 2001, 90, 454-460.
28. Carlson, C.J.; Koterski, S.; Sciotti, R.J.; Poccard, G.B.; Rondinone, C.M. Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Enhanced basal activation of mitogen-activated protein kinase in adipocytes from type 2 diabetes. Diabetes, 2003, 52, 634-641.
29. López-Aparicio, P.; Rascón, A.; Manganiello, V.C.; Andersson, K.E.; Belfrage, P.; Degerman, E. Insulin induced phosphorylation and activation of the cGMP-inhibited cAMP phosphodiesterase in human platelets. Biochem. Biophys. Res. Commun., 1992, 186, 517-523.
30. Trovati, M, Anfossi, G.; Cavalot, F.; Massucco, P.; Mularoni, E.; Emanuelli, G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes, 1988, 37, 780-786.
31. Trovati, M.; Anfossi, G.; Mularoni, E.; Massucco, P.; Bosia, A.; Emanuelli, G. Insulin reduces platelet sensitivity to Platelet Activating Factor in washed human platelets resuspended in a calcium-free medium. Diab. Nutr. Metab., 1989, 2, 151-153.
32. Trovati, M.; Anfossi, G.; Cavalot, F.; Massucco, P.; Mularoni, E.; Emanuelli, G. Physiological insulin concentrations reduce platelet sensitivity to adrenaline in vivo. In Frontiers in Diabetes. Tissue specific metabolic alterations in diabetes. Belfiore, F.; Molinatti, G.M.; Reaven, G.M.; Eds; Karger: Basel, 1990; Vol. 10, pp. 166-169.
33. Russo, I.; Massucco, P.; Mattiello, L.; Cavalot, F.; Anfossi, G.; Trovati, M. Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thromb. Res., 2002, 107, 31-37.
34. Russo, I.; Massucco, P.; Mattiello, L.; Anfossi, G.; Trovati, M. Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B29, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thromb. Res., 2003, 109, 323-327.
35. Toys, R.M.; Stiffing, E.L. Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregator responses in platelets from hypertensive patients. J. Hypertens., 1994, 12, 1255-1263.
36. Hiramatsu, K.; Nozaki, H.; Arimori, A. Reduction of platelet aggregation induced by euglycaemic insulin clamp. Diabetologia, 1987, 30, 310-313.
37. Westerbacka, J.; Yki-Jarvinen, H.; Turpeinen, A.; Rissanen, A.; Vehkavaara, S.; Syrjala, M.; Lassila, R. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 167-172.
38. Dutta-Roy, A.K.; Kahn, N.N.; Sinha, A.K. Interaction of receptors for prostaglandin E1/prostacyclin and insulin in human erythrocytes and platelets. Life Sci., 1991, 49, 1129-1239.
39. Trovati, M.; Massucco, P.; Mattiello, L.; Mularoni, E.; Cavalot, F.; Anfossi, G. Insulin increases guanosine-3′,5′-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect. Diabetes, 1994, 43, 1015-1019.
40. Trovati, M.; Massucco, P.; Mattiello, L.; Piretto, V.; Cavalot, F.; Mularoni, E.; Anfossi, G. The insulin-induced increase of guanosine-3′,5′-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes, 1996, 45, 768-770.
41. Trovati, M.; Anfossi, G.; Massucco, P.; Mattiello, L.; Costamagna, C.; Piretto, V.; Mularoni, E.; Cavalot, F.; Bosia, A.; Ghigo, D. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and adenosine-3′, 5′-cyclic monophosphate. Diabetes, 1997, 46, 742-749.
42. Trovati, M.; Anfossi, G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia, 1998, 41, 609-622
43. Trovati, M.; Anfossi, G. Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus. Curr. Diab. Rep., 2002, 2, 316-322.
44. Anfossi, G.; Trovati, M. Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy. Cardiovasc. Hematol. Agents Med. Chem., 2006, 4, 111-128.
45. Butt, E.; Abel, K.; Krieger, M.; Palm, D.; Hoppe, V.; Hoppe, J.; Walter, U. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem., 1994, 269, 14509-14517.
46. Yamanishi, J.; Kawahara, Y.; Fukuzaki, H. Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin2. Thromb. Res., 1983, 32, 183-188.
47. Kawahara, Y.; Yamanishi, Y.; Fukuzaki, H. Inhibitory action of guanosine 3′,5′-monophosphate on thrombin-induced calcium mobilization in human platelets. Thromb. Res. 1984, 33, 203-209.
48. Anfossi, G.; Russo, I.; Trovati, M. Platelet resistance to the anti-aggregating agents in the insulin resistant staes. Curr. Diab. Rev., 2006, 2, 409-430.
49. Udvardy, G.; Pflieger, G.; Rab, K. Platelet insulin receptor determination in non-insulin-dependent diabetes mellitus. Experientia, 1985, 41, 411-423.
50. Anfossi, G.; Mularoni, E.; Burzacca, S.; Ponziani, M.C.; Massucco, P.; Mattiello, L.; Perna, P.; Cavalot, F.; Trovati, M. Impaired platelet sensitivity to the anti-aggregating effects of adenosine in obesity and obese non-insulin-dependent diabetes mellitus. In Frontiers in Diabetes. Molecular and cell biology of type 2 diabetes and its complications. Belfiore, F.; Lorenzi, M.; Molinatti, G.M.; Porta, M, Eds., Karger, Basel, 1998, vol. 14, 184-187.
51. Trovati, M.; Mularoni, E.; Burzacca, S.; Ponziani, M.C.; Massucco, P.; Mattiello, L.; Piretto, V.; Cavalot; F.; Anfossi, G. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes, 1995, 44, 1318-1322.
52. Anfossi, G.; Mularoni, E.M.; Burzacca, S.; Ponziani, M.C.; Massucco, P.; Mattiello, L.; Cavalot, F.; Trovati, M. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care, 1998, 21, 121-126.
53. Anfossi, G.; Russo, I.; Massucco, P.; Mattiello, L.; Doronzo, G.; De Salve, A.; Trovati, M. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur. J. Clin. Invest., 2004, 34, 482-489.
54. Russo, I.; Traversa, M.; Bonomo, K.; Mattiello, L.; De Salve, A.; Fiora, E.; Doronzo, G.; Trovati, M.; Anfossi, G. Platelet resistance to nitric oxide donors, prostacyclin and anti-aggregating cyclic nucleotides in obese subjects is reverted by weight loss. Diabetologia, 2005, 48 (suppl 1), 706.
55. Ottlecz, A.; Geese, A.; Koltai, M.; West, G.B. Involvement of the kinin system in the insulin-induced inhibition of carrageenin oedema in rats. Monogr. Allergy, 1977, 12, 131-137.
56. Satomi, N.; Sakurai, A.; Haranaka, K. Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J. Natl. Cancer Inst., 1985, 74, 1255-1260.
57. Jeschke, M.G.; Einspanier, R.; Klein, D.; Jauch, K.W. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol. Med., 2002, 8, 443-450.
58. Garg, R.; Tripathy, D.; Dandona, P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic intervention. Curr. Drug Targets, 2004, 4, 487-492.
59. Aljada, A.; Ghanim, H.; Saadeh, R.; Dandona, P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J. Clin. Endocrinol. Metab., 2001, 86, 450-453.
60. Dandona, P.; Aljada, A.; Mohanty, P.; Ghanim, H.; Hamouda, W.; Assian, E.; Ahmad, S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J. Clin. Endocrinol. Metab., 2001, 86, 3257-3265.
61. Aljada, A.; Ghanim, H.; Mohanty, P.; Kapur, N.; Dandona, P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J. Clin. Endocrinol. Metab., 2002, 87, 1419-1422.
62. Dandona, P.; Aljada, A.; Mohanty, P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia, 2002, 45, 924-930.
63. de Winther, M.P.J.; Kanters, E.; Kraal, G.; Hofker, M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 904-914.
64. Adhikari, N.; Charles, N.; Lehmann, U.; Hall, J.L. Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr. Atheroscler. Rep., 2006, 8, 252-260.
65. Aljada, A.; Saadeh, R.; Assian, E.; Ghanim, H.; Dandona, P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells, through stimulation of nitric oxide. J. Clin. Endocrinol. Metab., 2000, 85, 2572-2575.
66. Aljada, A.; Dandona, P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism, 2000, 49, 147-150.
67. Chaudhuri, A.; Janicke, D.; Wilson, MF.; Tripathy, D.; Garg, R.; Bandyopadhyay, A.; Calieri, J.; Hoffmeyer, D.; Syed, T.; Ghanim, H.; Aljada, A.; Dandona, P. Anti-inflammatory and profibrinolytic effect of insulin in acute STsegment-elevation myocardial infarction. Circulation, 2004, 109, 849-854.
68. Shamir, R.; Shehadeh, N.; Rosenblat, M.; Eshach-Adiv, O.; Coleman, R.; Kaplan, M.; Hamoud, S.; Lischinsky, S.; Hayek, T. Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice. Arterioscler Thromb. Vasc. Biol., 2003, 23, 104-110.
69. Kubota, T.; Kubota, N.; Moroi, M.; Terauchi, Y.; Kobayashi, T.; Kamata, K.; Suzuki, R.; Tobe, K.; Namiki, A.; Aizawa, S.; Nagai, R.; Kadowaki, T.; Yamaguchi, T. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation, 2003, 107, 3073-3080.
70. Ceolotto, G.; Bevilacqua, M.; Papparella, I.; Baritono, E.; Franco, L.; Corvaja, C.; Mazzoni, M.; Semplicini, A.; Avogaro, A. Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3′-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes, 2004, 53, 1344-1351.
71. Steinberg, H.O.; Brechtel, G.; Johnson, A.; Fineberg, N.; Baron, A.D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest., 1994, 94, 1172-1179.
72. Scherrer, U.; Randin, D.; Vollenweider, P.; Vollenweider, L.; Nicod, P: Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest., 1994, 94, 2511-2515.
73. Mather, K.; Anderson, T.J.; Verma, S. Insulin action in the vasculature: physiology and pathophysiology. J. Vasc. Res., 2001, 38, 415-422.
74. Baron, A.D.; Clark, M.G. Role of blood flow in the regulation of muscle glucose uptake. Annu. Rev. Nutr., 1997, 17, 487-499.
75. Baron, A.D.; Steinberg, H.O.; Chaker, H.; Leaming, R.; Johnson, A.; Brechtel, G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J. Clin. Invest., 1995, 96, 786-792.
76. Pisters P.W.; Restifo NP.; Cersosimo, E.; Brennan, M.F. The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. Metabolism, 1991, 40, 59-65.
77. Laakso, M.; Edelman, S.V.; Olefsky, J.M.; Brechtel, G.; Wallace, P.; Baron, A.D. Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity. Diabetes, 1990, 39, 965-974.
78. Dela, F.; Larsen, J.J.; Mikines, K.J.; Galbo, H. Normal effect of insulin to stimulate leg blood flow in NIDDM. Diabetes, 1995, 44, 221-226.
79. Yki-Järvinen, H.; Utriainen, T. Insulin-induced vasodilation: physiology or pharmacology? Diabetologia, 1998, 41, 369-379.
80. Ferrannini, E.; Galvan, A.Q.; Gastaldelli, A.; Camastra, S.; Sironi, A.M.; Toschi, E.; Baldi, S.; Frascerra, S.; Monzani, F.; Antonelli, A.; Nannipieri, M.; Mari, A.; Seghieri, G.; Natali, A. Insulin: new roles for an ancient hormone. Eur. J. Clin. Invest., 1999, 29, 842-852.
81. Clark, M.G.; Wallis, M.G.; Barrett, E.J.; Vincent, M.A.; Richards, S.M.; Clerk, L.H.; Rattigan, S. Blood flow and muscle metabolism: a focus on insulin action. Am. J. Physiol. Endocrinol. Metab., 2003, 284, E241-E258.
82. Utriainen, T.; Malmström, R.; Mäkimattilä, S.; Yki-Järvinen, H. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia, 1995, 38, 555-564.
83. 18F]fluoro-2-deoxy-D-glucose, and positron emission tomography. Diabetes, 1996, 45, 1471-1477.
84. Utriainen, T.; Holmang, A.; Bjorntorp, P.; Mäkimattilä, S.; Sovijarvi, A.; Lindholm, H.; Yki-Järvinen, H. Physical fitness, muscle morphology, and insulin-stimulated limb blood flow in normal subjects. Am. J. Physiol., 1996, 270, E905-E911.
85. Utriainen, T.; Mäkimattiläm, S.; Virkamaki, A.; Lindholm, H.; Sovijarvi, A.; Yki-Järvinen, H. Physical fitness and endothelial function (nitric oxide synthesis) are independent determinants of insulin-stimulated blood flow in normal subjects. J. Clin. Endocrinol. Metab., 1996, 81, 4258-4263.
86. Sobrevia, L.; Nadal, A.; Yudilevich, D.L.; Mann, G.E. Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J. Physiol., 1996, 490, 775-781.
87. Arcaro, G.; Cretti, A.; Balzano, S.; Lechi, A.; Muggeo, M.; Bonora, E.; Bonadonna, R.C. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation, 2002, 105, 576-582.
88. Begum, N.; Duddy, N.; Sandu, O.; Reinzie, J.; Ragolia, L. Regulation of myosin-bound protein phosphatase by insulin in vascular smooth muscle cells: evaluation of the role of Rho kinase and phosphatidylinositol-3-kinase-dependent signaling pathways. Mol. Endocrinol., 2000, 14, 1365-1376.
89. McKay, M.K.; Hester, R.L. Role of nitric oxide, adenosine, and ATP-sensitive potassium channels in insulin-induced vasodilation. Hypertension, 1996, 28, 202-208.
90. Vincent, M.A.; Dawson, D.; Clark, A.D.; Lindner, J.R.; Rattigan, S.; Clark, M.G.; Barrett, E.J. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes, 2002, 51, 42-48.
91. Vincent, M.A.; Clerk, L.H.; Lindner, J.R.; Klibanov, A.L.; Clark, M.G.; Rattigan, S.; Barrett, E.J. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes, 2004, 53, 1418-1423.
92. Baron, A.D.; Brechtel-Hook, G.; Johnson, A.; Cronin, J.; Learning, R.; Steinberg, H.O. Effect of perfusion rate on the time course on insulin-mediated skeletal muscle glucose uptake. Am. J. Physiol., 1996, 271, E1067-E1072.
93. Mather, K.; Laakso, M.; Edelman, S.; Hook, G.; Baron, A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow Am. J. Physiol. Endocrinol. Metab., 2000, 279, E1264-E1270.
94. Rattigan, S.; Clark, M.G.; Barrett, E.J. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes, 1997, 46, 1381-1388.
95. Utriainen, T.; Nuutila, P.; Takala, T.; Vicini, P.; Ruotsalainen, U.; Ronnemaa, T.; Tolvanen, T.; Raitakari, M.; Haaparanta, M.; Kirvela, O.; Cobelli, C.; Yki-Järvinen, H. Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J. Clin. Invest., 1997, 100, 777-785.
96. + exchange by insulin in the human forearm. Am. J. Physiol., 1988, 255, E953-E958.
97. Nuutila, P.; Raitakari, M.; Laine H.; Kirvelä, O.; Takala, T.; Utriainen, T.; Mäkimattila, S.; Pitkänen, O-P.; Ruotsalainen, U.; Iida, H.; Knuuti, J.; Yki-Järvinen, H. Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J. Clin. Invest., 1996, 97, 1741-1747.
98. Natali, A.; Bonadonna, R.; Santoro, D.; Galvan, A.Q.; Baldi, S.; Frascerra, S.; Palombo, C.; Ghione, S.; Ferrannini, E. Insulin resistance and vasodilatation in essential hypertension. Studies with adenosine. J. Clin. Invest., 1994, 94, 1570-1576.
99. Natali, A.; Quinones Galvan, A.; Pecori, N.; Sanna, G.; Toschi, E.; Ferrannini, E. Vasodilation with sodium nitroprusside does not improve insulin action in essential hypertension. Hypertension, 1998, 31, 632-636.
100. Cardillo, C.; Nambi, S.S.; Kilcoyne, C.M.; Choucair, W.K.; Katz, A.; Quon, M.J.; Panza, J.A. Insulin stimulates both endothelin and nitric oxide activity in human forearm. Circulation, 1999, 100, 820-825.
101. Sartori, C.; Scherrer, U. Insulin, nitric oxide and the sympathetic nervous system: at the crossroad of metabolic and cardiovascular regulation. J. Hypertens., 1999, 17, 1517-1525.
102. Rowe, J.W.; Young, J.B.; Minaker, K.L.; Stevens, A.L.; Pallotta, A.; Landsberg, L. Effect of insulin and glucose infusions on sympathetic nervous systrmactivity in normal man. Diabetes, 1981, 30, 219-225.
103. Anderson, E.A.; Hoffman, R.P.; Balon, T.W.; Sinkey, C.A.; Mark, A.L. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J. Clin. Invest., 1991, 87, 2246-2252.
104. Scherrer, U.; Vollenweider, P.; Randin, D.; Jequier, E.; Nicod, P.; Tappy, L. Suppression of insulin induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation, 1993, 88, 388-394.
105. Lembo, G.; Napoli, R.; Capaldo, B.; Rendina, V.; Iaccarino, G.; Volpe, M.; Trimarco, B.; Saccà, L. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J. Clin. Invest., 1992, 90, 24-29.
106. Sundell, J.; Nuutila, P.; Laine H.; Luotolahti, M.; Kalliokoski, K.; Raitakari, O.; Knuuti, J. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes, 2002, 51, 1125-1130.
107. Vollenweider, P.; Tappy, L.; Randin, D.; Schneiter, P.; Jequier, E.; Nicod, P.; Scherrer, U. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J. Clin. Invest., 1993, 92, 147-154.
108. Scherrer, U.; Randin, D.; Tappy, L.; Vollenweider, P.; Jequier, E.; Nicod, P. Body fat and sympathetic nerve activity in healthy subjects. Circulation, 1994, 89, 2634-2640.
109. Baskin, DG.; Figlewicz, D.P.; Woods, S.C.; Porte, D.; Dorsa, D.M. Insulin in the brain. Annu. Rev. Physiol., 1987, 49, 335-347.
110. Esler, M.; Straznicky, N.; Eikelis, N.; Masuo, K.; Lambert, G.; Lambert, E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension, 2006, 48, 787-796.
111. Muntzel, M.S. Insulin-mediated sympathoexcitation in obesity and type 2 diabetes. Nephrol. Dial. Transplant., 1999, 14, 2282-2285.
112. Spraul, M.; Ravussin, E.; Baron, A.D. Lack of relationship between muscle sympathitic nerve activity and skeletal muscle vasodilation in response to insulin infusion. Diabetologia, 1996, 39, 91-96.
113. Berne, C.; Fagius, J.; Niklasson, F. Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. J. Clin. Invest., 1989, 84, 1403-1409.
114. Paramore, D.S.; Fanelli, C.G.; Shah, S.D.; Cryer, P.E. Forearm norepinephrine spillover during standing, hyperinsulinemia, and hypoglycemia. Am. J. Physiol., 1998, 275, E872-E881.
115. Dela, F.; Stallknecht, B.; Biering-Sorensen, F. An intact central nervous system is not necessary for insulin-mediated increases in leg blood flow in humans. Pflugers Arch., 2000, 441, 241-250.
116. Randin, D.; Vollenweider, P.; Tappy, L.; Jequier, E.; Nicod, P.; Scherrer, U. Effects of adrenergic and cholinergic blockade on insulin-induced stimulation of calf blood flow in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol., 1994, 266, R809-R816.
117. Porcellati, F.; Fanelli, C.; Bottini, P.; Epifano, L.; Rambotti, A.M.; Lalli, C.; Campanelli, S.; Scionti, L, Santeusanio, F.; Brunetti, P. Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. Diabetes, 1993, 42, 1055-1064.
118. Makimattila, S.; Mantysaari, M.; Schlenzka, A.; Summanen, P.; Yki Järvinen, H. Mechanisms of altered hemodynamic and metabolic responses to insulin in patients with insulin-dependent diabetes mellitus and autonomic dysfunction. J. Clin. Endocrinol. Metab., 1998, 83, 468-475.
119. Sartori, C.; Trueb, L.; Nicod, P.; Scherrer, U. Effects of sympathectomy and nitric oxide synthase inhibition on vascular actions of insulin in humans. Hypertension, 1999, 34, 586-589.
120. Hausberg, M.; Mark,. AL.; Hoffman, R.P.; Sinkey, C.A.; Anderson, E.A.. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J. Hypertens., 1995, 13, 1015-1021.
121. Vollenweider, P.; Randin, D.; Tappy, L.; Jequier, E.; Nicod, P.; Scherrer, U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J. Clin. Invest., 1994, 93, 2365-2371.
122. Landsberg, L.; Krieger, D.R. Obesity, metabolism, and the sympathetic nervous system. Am. J. Hypertens., 1989, 2, 125S-132S.
123. DeFronzo, R.A. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia, 1981, 21, 165-171.
124. Moore RD. Effect of insulin upon ion transport. Biochem. Biophys. Acta, 1983, 737, 1-49.
125. Sarafidis, P.A.; Baluis, G.L. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am. J. Nephrol., 2007, 27, 44-54.
126. Sarafidis, P.A.; Bakris, G.L. Insulin and endothelin: an interplay contributing to hypertension, development? J. Clin. Endocrinol. Metab., 2007, 92, 379-385.
127. Reaven, G.M.; Lithell, H.; Landsberg, L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med., 1996, 334, 374-381.
128. Reaven, P.D.; Barrett-Connor, E.L.; Browner, D.K. Abnormal glucose tolerance and hypertension. Diabetes Care, 1990, 13, 119-125.
129. Cambien, F.; Warnet, J.M.; Eschwege, E.; Jacqueson, A.; Richard, J.L.; Rosselin, G. Body mass, blood pressure, glucose, and lipids. Does plasma insulin explain their relationships? Arteriosclerosis, 1987, 7, 197-202.
130. Mbanya, J.C.; Thomas, T.H.; Wilkinson, R.; Alberti, K.G.; Taylor, R. Hypertension and hyperinsulinemia: a relationship in diabetes but not in essential hypertension. Lancet, 1988, 1, 733-734.
131. Creager, M.A.; Liang, C-S.; Coffman, J.D. β-Adrenergic-mediated vasodilator response to insulin in the human forearm. J. Pharmacol. Exp. Ther., 1985, 235, 709-714.
132. Scott, A.R.; Bennett, T.; MacDonald, I.A. Effects of hyperinsulinaemia on the cardiovascular responses to graded hypovolaemia in normal and diabetic subjects. Clin. Sci., 1988, 75, 85-92.
133. Baron, A.D.; Brechtel-Hook, G.; Johnson, A.; Hardin, D. Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension, 1993, 21, 129-135.
134. Vincent, M.A.; Montagnani, M.; Quon, M.J. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr. Diab. Rep., 2003, 3, 279-288.
135. Heise, T.; Magnusson, K.; Heinemann, L.; Sawicki P.T. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension, 1998, 32, 243-248.
136. Anfossi, G.; Trovati, M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J. Clin. Invest., 1996, 26, 353-370.
137. Tsang, A.; Hausentoy, D.J.; Yellon, D.M. Myocardial postconditioning: reperfusion injury revisited. Am. J. Physiol. Heart Circ. Physiol., 2005, 289, H2-H7.
138. Jonassen, A.K.; Sack, M.N.; Mjos, O.D.; Yellon, D.M. Myocardial protection by insulin at reperfusion required early administration and is mediated via Akt and p70S6 kinase cell-survival signaling. Circ. Res., 2001, 89, 1191-1198.
139. Morisco, C.; Lembo, G.; Trimarco, B. Insulin resistance and cardiovascular risk: new insights from molecular and cellular biology. Trends Cardiovasc. Med., 2006, 16, 183-188.
140. Aikawa, R.; Nawano, M.; Gu Y.; Katagiri, H.; Asano, T.; Zhu, W.; Nagai, R.; Komuro, I. Insulin prevents cardiomyocytes from oxidative stress-induced spoptosis through activation of P13 kinase/Akt. Circulation, 2000, 102, 2873-2879.
141. Gao, F.; Gao, E.; Yuc, T.L.; Ohlstein,. EH.; Lopez, B.L.; Christopher, T.A.; Ma, X.L. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion. The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation, 2002, 105, 1497-1502.
142. Ma, H.; Zhang, H.F.; Yu, L.; Zhang, Q.J.; Li, J.; Huo, J.H.; Li, X.; Guo W.Y.; Wang, H.C.; Gao, F. Vasculoprotective effect of insulin in the ischemic/reperfused canine heart: role of Akt-stimulated NO production. Cardiovasc. Res., 2006, 69, 57-65.
143. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res., 2004, 61, 448-460.
144. Abdallah, Y.; Gkatzoflia, A.; Pieper, H.; Zoga, E.; Walther, S.; Kasseckert, S.; Schafer, M.; Schluter, K.D.; Piper, H.M.; Schafer, C. Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion innjury. Cardiovasc. Res., 2005, 66, 123-131.
145. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell. Physiol., 2001, 280, C1358-C1366.
146. Jialal, I.; Crettaz, M.; Huchiya, H.L.; Kahn, C.R.; Moses, A.C.; Buzney, S.M.; King, G.L. Characterization of the receptors for insulin and insulin-like growth factors on micro- and macrovascular tissues. Endocrinology, 1985, 117, 1222-1229.
147. Bar, R.S.; Peacock, M.L.; Spanheimer, R.G.; Veenstra, R.; Hoak, J.C. Differential binding of insulin to human arterial and venous endothelial cells in primary culture. Diabetes, 1980, 29, 991-995.
148. King, G.L.; Buzney, S.M.; Kahn, C.R.; Hetu, N.; Buchwald, S.; Macdonald, S.G.; Rand, L.I. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J. Clin. Invest., 1983, 71, 974-979.
149. Ding, Y.; Vaziri, N.D.; Coulson, R.; Kamanna, V.S.; Roh, D.D. Effects of simulated hyperglycemia, insulin, a glucagon on endothelial nitric oxide synthase expression. Am. J. Physiol. Endocrinol. Metab., 2000, 279, E11-E17.
150. Kuboki, K.; Jiang, Z.Y.; Takahara, N.; Ha, S.W.; Igarashi, M.; Yamauchi, T.; Feener, E.P.; Herbert; T.P.; Rhodes, C.J.; King, G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular effect of insulin. Circulation, 2000, 101, 676-681.
151. Hermann, C.; Assmus, B.; Urbich, C.; Zeiher, A.M.; Dimmeler, S. Insulin-mediated stimulation of protein kinase Akt: a potential survival signaling cascade for endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 402-409.
152. Zeng, G.; Nystrom, F.H.; Ravichandran, L.V.; Cong, L.N.; Kirby, M.; Mostowski, H.; Quon, M.J. Roles for insulin receptor, P13-kinase, and Akt in insulin signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation, 2000, 101, 1539-1545.
153. Zeng, G.; Quon, M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest., 1996, 98, 894-898.
154. Du, X.L.; Edelstein, D.; Dimmeler, S.; Ju, Q.; Sui, C.; Brownlee, M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest., 2001, 108, 1341-1348.
155. Montagnani, M.; Chen, H.; Barr, V.A.; Quon, M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem., 2001, 276, 30392-39398.
156. Baron, A.D. Insulin resistance and vascular function. J. Diab. Compl., 2002, 16, 92-102.
157. Kim, J.; Montagnani, M.; Koh, K.K.; Quon, M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction, Molecular and pathopysiological mechanisms. Circulation, 2006, 113, 1888-1904.
158. 616 in human umbilical vein endothelial cells. Circ. Res., 2004, 94, 1211-1218.
159. Moncada, S.; Palmer, R.M.J.; Higgs, E.A. The discovery of nitric oxide as the endogenous vasodilator. Hypertension, 1988, 12, 365-372.
160. Garg, U.C.; Hassid, A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest., 1989, 83, 1774-1777.
161. Puente Navazo, M.D.; Chettab, K.; Duhault, J.; Koenig-Berard, E.; McGregor, J.L. Glucose and insulin modulate the capacity of endothelial cells (HUVEC) to express P-selectin and bind monocytic cell lines (U937). Thromb. Haemost., 2001, 86, 680-685.
162. Masaki, T. The discovery of endothelins. Cardiovasc. Res., 1998, 39, 530-533.
163. Filep, J.G.; Sirois, M.G.; Foldes-Filep, E.; Rousseau, A.; Plante, G.E.; Fournier, A.; Yano, M.; Sirois, P. Enhancement of endothelin-1 of microvascular permeability via the activation of ETA receptors. Br. J. Pharmacol., 1993, 109, 880-886.
164. Bobik, A.; Grooms, A.; Millar, J.A.; Mitchell, A.; Grinpukel, S. Growth factor activity of endothelin on vascular smooth muscle. Am. J. Physiol., 1990, 258, C408-C415.
165. Stankova, J.; Rola-Pleszczynski, M.; D'Orleans-Juste, P. Endothelin 1 and thrombin synergistically stimulate IL-6 mRNA expression and protein production in human umbilical vein endothelial cells. J. Cardiovasc. Pharmacol., 1995, 26 (Suppl 3), S505-S507.
166. McMillen, M.A.; Huribal, M.; Cunningham, M.E.; Kumar, R.; Sumpio, B.E. Endothelin-1 increases intracellular calcium in human monocytes and causes production of interleukin-6. Crit. Care Med., 1995, 23, 34-40.
167. Oliver, F.J.; de la Rubia, G.; Feener, E.P.; Lee, M.E.; Loeken, M.R.; Shiba, T.; Quertermous, T.; King, G.L. Stimulation of endothelin-1 gene by insulin in endothelial cells. J. Biol. Chem., 1991, 266, 23251-23256.
168. Hu, R.M. Levin, E.R.; Pedram, A.; Frank, H.J. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes, 1993, 42, 351-358.
169. Anfossi, G.; Cavalot, F.; Massucco, P.; Mattiello, L.; Mularoni, E.; Hahn, A.; Trovati, M. Insulin influences immunoreactive endothelin release by vascular smooth muscle cells. Metabolism, 1993, 42, 1081-1083.
170. Bakris, G.L.; Re, R.N. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am. J. Physiol., 1993, 264, F937-F942.
171. Potenza, M.A.; Marasciulo, F.L.; Chieppa, D.M.; Brigiani, G.S.; Formoso, G.; Quon, M.J.; Montagnani, M. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am. J. Physiol. Heart Circ. Physiol., 2005, 298, H813-H822.
172. Metsarinne, K.; Saijonmaa, O.; Yki-Järvinen, H.; Fyhrquist, F. Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism, 1994, 43, 878-882.
173. Leyva, F.; Wingrove, C.; Felton, C.; Stevenson, J.C. Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals. Metabolism, 1997, 56, 1137-1139.
174. Piatti, P.M.; Monti, L.D.; Conti, M.; Baruffaldi, L.; Galli, L.; Phan, C.V.; Guazzini, B.; Pontiroli, A.E.; Pozza, G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes, 1996, 45, 316-321.
175. Donatelli, M.; Colletti, I.; Bucalo, M.L.; Russo, V.; Verga, S. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res., 1994, 25, 159-164.
176. Donatelli, M.; Hoffmann, E.; Colletti, I. Andolina, G.; Russo, V.; Bucalo, M.L.; Valenti, T.M.; Compagno, V.; Cataldo, M.G.; Morici, M.L. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol., 1996, 33, 246-248.
177. Ferri, C.; Laurenti, O.; Bellini, C.; Faldetta, M.R.; Properzi, G.; Santucci, A.; De Mattia, G. Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Influence of ACE inhibition. Am. J. Hypertens., 1995, 8, 40-47.
178. Ferri, C.; Bellini, C.; Desideri, G.; Baldoncini, R., Properzi, G.; Santucci, A.; De Mattia, G. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp. Clin. Endocrinol. Diabetes, 1997, 105 (suppl 2), 38-40.
179. Ferri, C.; Bellini, C.; Desideri, G.; Di Francesco, L.; Baldoncini, R.; Santucci, A.; De Mattia, G. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes, 1995, 44, 431-436.
180. Takahashi, K.; Ghatei, M.A.; Lam, H.C.; O'Halloran, D.J.; Bloom, S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia, 1990, 33, 306-310.
181. Mangiafico, R.A.; Malatino, L.S.; Santonocito, M.; Spada, R.S. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int. Angiol., 1998, 17, 97-102.
182. Piatti, P.M.; Monti, L.D.; Galli, L.; Fragasso, G.; Valsecchi, G.; Conti, M.; Gemone, F.; Pontiroli, A.E. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism, 2000, 49, 748-752.
183. Ferri, C.; Pittoni, V.; Piccoli, A.; Laurenti, O.; Cassone, M.R.; Bellini, C.; Properzi, G.; Valesini, G.; De Mattia, G.; Santucci, A. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J. Clin. Endocrinol. Metab., 1995, 80, 829-835.
184. Maeda, S.; Jesmin, S.; Iemitsu, M.; Otsuki, T.; Matsuo, T.; Ohkawara, K.; Nakata, Y.; Tanaka, K.; Goto, K.; Miyauchi, T. Weight loss reduces plasma endothelin-1 concentration in obese men. Exp. Biol. Med., 2006, 231, 1044-1047.
185. Juan, C.C.; Fang, V.S.; Huang, Y.J.; Kwok, C.F.; Hsu, Y.P.; Ho, L.T. Endothelin-1 induces insulin resistance in conscious rats. Biochem. Biophys. Res. Commun., 1996, 227, 694-699.
186. Lee, Y.C.; Juan, C.C.; Fang, V.S.; Hsu, Y.P.; Lin, S.H.; Kwok, C.F.; Ho, L.T. Evidence that endothelin-1 (ET-1) inhibits insulin-stimulated glucose uptake in rat adipocytes mainly through ETA receptors. Metabolism, 1998, 47, 1468-1471.
187. Ottosson-Seeberger, A.; Lundberg, J.M.; Alvestrand, A.; Ahlborg, G. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol. Scand., 1997, 161, 211-220.
188. Wilkes, J.J.; Hevener, A.; Olefsky, J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes, 2003, 52, 1904-1909.
189. Vinters, H.V.; Berliner, J.A. The blood vessel wall as an insulin target tissue. Diabete Metab., 1987, 13, 294-300.
190. Taggart, H.; Stout, R.W. Control of DNA synthesis in cultured vascular endothelial and smooth muscle cells - response to serum, platelet-deficient serum, lipid-free serum, insulin and oestrogens. Atherosclerosis, 1980, 37, 549-557.
191. Nakao, J.; Ito, H.; Kanayasu, T.; Murota, S. Stimulatory effect of insulin on aortic smooth muscle cells migration induced by 12-L-hydroxy-5, 8,10,14-eicosatetraenoic acid and its modulation by elevated extracellular glucose levels. Diabetes, 1985, 34, 185-191.
192. Obata, T.; Kashiwagi, A.; Maegawa, H.; Nishio, Y.; Ugi, S.; Hidaka, H.; Kikkawa, R. Insulin signaling and its regulation of system A amino acid uptake in cultured rat vascular smooth muscle cells. Circ. Res., 1996, 79, 1167-1176.
193. Nigro, J.; Osman, N.; Dart, A.M.; Little, P.J. Insulin resistance and atherosclerosis. Endocr. Rev., 2006, 27, 242-259.
194. Bergandi, L.; Silvagno, F.; Russo, I.; Riganti, C.; Anfossi, G.; Aldieri, E.; Ghigo, D.; Trovati, M.; Bosia, A. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 2215-2221.
195. Wang, C.C.; Gurevich, I; Draznin, B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes, 2003, 52, 2562-2569.
196. Banskota, N.K.; Taub, R.; Zellner, K.; King, G.L. Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol., 1989, 3, 1183-1190.
197. Cavalot, F.; Russo, I; Mattiello, L.; Anfossi, G.; Massucco, P.; Mularoni, E, Hahn, A.W.; Trovati, M. Influence of protamine on adhesion, chemotaxis and proliferation of human vascular smooth muscle cells. Diabetologia, 1997, 40, 67-75.
198. Russo, I; Del Mese, P.; Doronzo, G.; Mattiello, L.; Anfossi, G.; Trovati M. Aortic vascular smooth muscle cells from obese Zucker rats show increased proliferative response to serum in comparison to those from lean Zucker rats: involvement of MAPK and VASP activation. Diabetologia, 2006, 49 (suppl 1), 732.
199. Trovati, M.; Massucco, P.; Mattiello, L.; Cavalot, F.; Mularoni, E.; Hahn, A.; Anfossi, G. Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetologia, 1995, 38, 936-941.
200. Trovati, M.; Massucco, P.; Mattiello, L.; Costamagna, C.; Aldieri, E.; Cavalot, F.; Anfossi, G.; Bosia, A.; Ghigo, D. Human vascular smooth muscle cells express a constitutive nitric oxide synthase that insulin rapidly activates, thus increasing guanosine 3':5'-cyclic monophosphate and adenosine 3':5'-cyclic monophosphate concentrations. Diabetologia, 1999, 42, 831-839.
201. Kahn, A.M.; Husid, A.; Allen, J.C.; Seidel, C.L.; Song, T. Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. Hypertension, 1997, 30, 928-933.
202. +-ATPase gene expression by insulin in vascular smooth muscle cells. Am. J. Hypertens., 1993, 6, 626-629.
203. +-K6+-ATPase activity by nitric oxide: a cGMP-independent effect. Am. J. Physiol., 1994, 266, H2146-2151.
204. Olefsky, J.; Farquhar, J.W.; Reaven, G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes, 1973, 22, 507-513.
205. Steinberg, H.O.; Tarshoby, M.; Monestel, R.; Hook, G.; Cronin, J.; Johnson, A.; Bayazeed, N.; Baron, A.D. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin. Invest., 1997, 100, 1230-1239.
206. Holmang, A.; Nilsson, C.; Niklasson, M.; Larsson, B.M.; Lonroth P. Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin. Diabetes, 1999, 48, 106-111.
207. Hsueh, W.A.; Quinones, M.J. Role of endothelial dysfunction in insulin resistance. Am. J Cardiol., 2003, 92 (suppl 4A), 10J-17J.
208. McVeigh, G.E.; Brennan, G.M.; Johnston, G.D.; McDermott, B.J.; McGrath, L.T.; Henry, W.R.; Andrews, J.W.; Hayes, J.R. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35, 771-776.
209. Steinberg, H.O.; Chaker, H.; Leaming, R.; Johnson, A.; Brechtel, G.; Baron, A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest., 1996, 97, 2601-2610.
210. Hogikyan, R.V.; Galecki, A.T.; Pitt, B.; Halter, J.B.; Greene, D.A. Supiano, M.A. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J. Clin. Endocrinol. Metab., 1999, 83, 1946-1952.
211. Baron, A.D.; Laakso, M.; Brechtel, G.; Edelman, S.V. Reduced capacity and affinity of skeletal muscle for insutin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy. J. Clin. Invest., 1991, 87, 1186-1194.
212. Cleland, S.J.; Petrie, J.R.; Ueda, S.; Elliott, H.L.; Connell, J.M.C. Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension, 1999, 33, 554-558.
213. Cosentino, F.; Luscher, T.F. Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol., 1999, 32 (Suppl 3), S54-S61.
214. Hwang, S.J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M.; Boerwinkle, E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary hearts disease cases. The Atherosclerosis Risk in Communities (ARIC) study. Circulation, 1997, 96, 4219-4225.
215. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma concentration of soluble intracellular adhesion molecule-1 and risk of future myocardial infarction in apparently healthy men. Lancet, 1998, 351, 88-92.
216. Malik, I; Danesh, J.; Whincup, P.; Bliatia, V.; Papacosta, O.; Walker, M.; Lennon, L.; Thomson, A.; Haskard, D. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet, 2001, 358, 971-976.
217. Abe, H.; Yamada, N.; Kamata, K.; Kuwaki, T.; Shamida, M.; Osuga, J, Shionoiri, F.; Yahagi, N.; Kadowaki, T.; Tamemoto, H.; Ishibashi, S.; Yazaki, Y.; Makuuchi, M. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest., 1998, 101, 1784-1788.
218. Laakso, M.; Edelman, S.V.; Brechtel, G.; Baron, A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J. Clin. Invest., 1990, 85, 1844-1852.
219. Laakso, M.; Edelman, S.V.; Brechtel, G.; Baron, A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NlDDM. Diabetes, 1992, 41, 1076-1083.
220. Shankar, R.R.; Wu, Y.; Shen, H.Q.; Zhu, J.S.; Baron, A.D. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes, 2000, 49, 684-687.
221. Lavrencic, A.; Salobir, B.G.; Keber, I. Physical training improves flow-mediated dilation in patients with the polymetabotic syndrome. Arterioscler Thromb. Vasc. Biol., 2000, 20, 551-555.
222. Verma, S.; Yao, L.; Dumont, A.; McNeill, J. Metformin treatment corrects vascular insulin resistance in hypertension. J. Hypertens., 2000, 18, 1445-1450.
223. Mather, K.J.; Verma, S.; Anderson, T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 2001, 37, 1344-1350.
224. Sung, B.H.; Izzo, J.L. Jr, Dandona, P.; Wilson, M.F. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellims. Hypertension, 1999, 34, 83-88.
225. Federici, M.; Pandolfi, A.; De Filippis, E.A.; Pellegrini, G.; Menghini, R.; Lauro, D.; Cardellini, M.; Romano, M.; Sesti, G.; Lauro, R.; Consoli, A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation, 2004, 109, 399-405.
226. Montagnani, M.; Golovchenko, I.; Kim, L; Goalstone, M.L.; Mundhekar, AX; Johansen, M.; Kucik, D.F.; Quon, M.J.; Draznin, B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endodiefial cells. J. Biol. Chem., 2002, 277, 1794-1799.
227. Scherrer, U.; Sartori, C. Insulin as a vascular and sympathoexcitatory hormone. Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation, 1997, 96, 4104-4113.
228. Vita, JA.; Treasure, C.B.; Yeung, A.C.; Vekshtein, V.I.; Fantasia, G.M.; Ganz, P.; Selwyn, A. P. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation, 1992, 85, 1390-1397.
229. von Kdsanel, R.; Dimsdale, J.E. Effects of sympathetic activation by adrenergic infasions on hemostasis in vivo. Eur J. Haematol., 2000, 65, 357-369.
230. Diaz, R.; Paolasso, E.A.; Piegas, L.S.; Tajer, C.D.; Moreno, M.G.; Corvalan, R.; Isea, J.E.; Romero, G. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos latinoamerica) Collaborative Group. Circulation, 1998, 98, 2227-2234.
231. Fath-Ordoubadi, F.; Beatt, K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized. placebo-controlled trials. Circulation, 1997, 96, 1152-1156.
232. Malmberg, K.; Norhammar, A.; Wedel, H.; Ryden, L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation, 1999, 99, 2626-2632.
233. Van den Berghe, G.; Wouters, P.; Weekers, F.; Verwaest, C.; Bruyninckx, F.; Schetz, M.; Vlasselaers, D.; Ferdinande, P.; Lauwers, P.; Bouillon, R. Intensive insulin therapy in critically ill patients. N. Engl. J. Med., 2001, 345, 1359-1367.
234. Krinsley, J.S. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin. Proc., 2003, 78, 1471-1478.
235. Krinsley, J.E. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. 2004, 79, 992-1000.
236. Van den Berghe, G.; Wouters, P.J.; Bouillon, R.; Weekers, F.; Verwaest, C.; Schetz, M.; Vlasselaers, D.; Ferdinande, P.; Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit. Care Med., 2003, 31, 359-366.
237. Pittas, A.G.; Siegel, R.D.; Lau, J. Insulin therapy for critically ill hospidalized patients: a meta-analysis of randomized controlled trials. Arch. Intern. Med., 2004, 164, 2005-2011.
238. Andreelli, F.; Jacquier, D.; Troy, S. Molecular aspects of insulin therapy in critically ill patients. Curr Opin. Clin. Nutr Metab. Care, 2006, 9, 124-130.
239. Langouche, L.; Vanhorebeek, I.; Vlasselaers, D.; Vander Perre, S.; Wouters, P.J.; Skogstrand, K.; Hansen, K.; Van den Berghe, G. Intensive insulin therapy protects the endothelium of critically ill patients. J. Clin. Invest., 2005, 115, 2277-2286.
240. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation, 2005, 111, 1448-1454.
241. Tian, R.; Balschi, J.A. Interaction of insulin and AMPK in the ischemic heart: another chapter in the book of metabolic therapy? Circ. Res., 2006, 99, 3-5.
242. Van den Berghe, G. How does blood glucose control with insulin save lives in intensive care? J. Clin. Invest., 2004, 114, 1187-1195.
243. Takala, T.O.; Nuutila, P.; Katoh, C.; Luotolahti, M.; Bergman, J.; Maki, M.; Oikonen, V.; Ruotsalainen, U.; Gronroos, T.; Haaparanta, M.; Kapanen, J.; Knuuti, J. Myocardial blood flow, oxygen consumption, and fatty acid uptake in endurance athletes during insulin stimulation. Am. J. Physiol., 1999, 277, E585-E590.
244. Laine, H.; Nuutila, P.; Luotolahti, M.; Meyer, C.; Elomaa, T.; Koskinen, P.; Ronnemaa, T.; Knuuti, J. Insulin-induced increment of coronary flow reserve is not abolished by dexamethasone in healthy young men. J. Clin. Endocrinol. Metab., 2000, 85, 1868-1873.
245. McNulty, P.H.; Pfau, S.; Deckelbaum, L.I. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. Am. J. Cardiol., 2000, 85, 161-165.
246. Marano, L.; Bestetti, A.; Lomuscio, A.; Tagliabue, L.; Castini, D.; Tarricone, D.; Dario, P.; Tarolo, G.L.; Fiorentini, C. Effects of infusion of glucose-insulin-potassium on myocardial function after a recent myocardial infarction. Acta Cardiol., 2000, 55, 9-15.
247. Lautamaki, R.; Airaksinen K.E.; Seppanen, M.; Toikka, J.; Harkonen, R.; Luotolahti, M.; Borra, R.; Sundell, J.; Knuuti, J.; Nuutila, P. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease. Diabetes, 2006, 55, 511-516.
248. Sodi-Palliares, D.; Testelli, M.R.; Fishleder, B.L. Effect of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction, A preliminary report. Am. J. Cardiol., 1962, 9, 166-181.
249. Doenst, T.; Bothe, W.; Beyersdorf, F. Therapy with insulin in cardiac surgery: controversies and possible solutions. Ann. Thorac. Surg., 2003, 75, S721-S728.
250. Lazar, H.L.; Philippides, G.; Fitzgerald, C.; Lancaster, D.; Shemin, R.J.; Apstein, C. Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., 1997, 113, 354-360.
251. Lazar, H.L.; Zhang, X.; Rivers, S.; Bernard, S.; Shemin, R.J. Limiting ischemic myocardial damage using glucose-insulin-potassium solutions. Ann. Thorac. Surg., 1995, 60, 411-416.
252. Bothe, W.; Olschewski, M.; Beyersdorf, F.; Doenst, T. Glucose-insulin-potassium in cardiac surgery: a meta-analysis. Ann. Thorac. Surg., 2004, 78, 1650-1657.
253. Fava, S.; Aquilina, O.; Azzopardi, J.; Agius Muscat, H.; Fenech, F.F. The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabet. Med., 1996, 13, 80-83.
254. Lazar, H.L.; Chipkin, S.; Philippides, G.; Bao, Y.; Apstein, C. Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann. Thorac. Surg., 2000, 70, 145-150.
255. Sundell, J.; Knuuti, J. Insulin and myocardial blood flow. Cardiovasc. Res., 2003, 57, 312-319.
256. Gradinac, S.; Coleman, G.M.; Taegtmeyer, H.; Sweeney, M.S.; Frazier, O.H. Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting. Ann. Thorac. Surg., 1989, 48, 484-489.
257. Dudek, H.; Datta, S.R.; Franke, T.F.; Birnbaum M.J.; Yao, R.; Cooper, G.M.; Segal, R.A.; Kaplan, D.R.; Greenberg, M.E. Regulation of neuronal survival by the serine-threonine protein kimase Akt. Science, 1997, 275, 661-565.
258. Devos, P.; Chiolero, R.; Van den Berghe, G.; Preiser, J.C. Glucose, insulin and myocardial ischaemia. Curr Opin. Clin. Nutr Metab. Care, 2006, 9, 131-139.
259. Nakazawa, T.; Chiba, T.; Kaneko, E.; Yui, K.; Yoshida, M,, Shimokado, K. Insulin signaling in arteries prevents smooth muscle apoptosis. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 760-765.
260. Khoynezhad, A.; Jalali, Z.; Tortolani, A.J. Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon. Ann. Thorac. Surg., 2004, 78, 1109-1118.
261. Zhang, L.; Zhang, L.; Li, Y.H.; Chen, M.L.; Gao, M.M.; Hu, A.H.; Yang, H.S.; Yang, H.S. High-dose glucose-insulin-potassium treatment reduces myocardial apoptosis in patients with acute myocardial infarction. Eur. J. Clin. Invest., 2005, 35, 164-170.
262. Voll, C.L.; Auer, R.N. Insulin attenuates ischemic brain damage independently of its hypoglycemic effects. J. Cereb. Blood Flow Metab., 1991, 11, 1006-1014.
263. Hamilton, M.G.; Tranmer, B.I.; Auer, R.N. Insulin reduction of cerebral infarction due to transient focal ischemia. J. Neurosurg., 1995, 82, 262-268.
264. Duarte, A.I.; Santos, M.S.; Oliveira, C.R.; Rego, A.C. Insulin neuroprotection against oxidative stress in cortical neurons-involvement of uric acid and glutathione antioxidant defenses. Free Radic. Biol. Med., 2005, 39, 876-889.
265. Yuan, Z.R.; Liu, B.; Zhang, Y.; Yuan, L.; Muteliefu, G.; Lu, J. Upregulated expression of neuronal nitric oxide synthase by insulin in both neurons and astrocytes. Brain Res., 2004, 1008, 1-10.
266. Scott, J.F.; Robinson, G.M.; French, J.M.; O'Connell, J.E.; Alberti, K.G.; Gray, C.S. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke, 1999, 30, 793-799.
267. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Part 9: Adult Stroke Circulation, 2005, 112, IV-111-IV-120.
268. Garg, R.; Chaudhuri, A.; Munschauer, F.; Dandona, P. Hyperglycemia, insulin, and acute stroke. A mechanistic justification for a trial of insulin infusion therapy. Stroke, 2006, 37, 267-273.
269. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352, 837-853.
270. Laakso, M. How good a marker is insulin level for insulin resistance? Am. J Epidemiol., 1993, 137, 959-965.
271. Mykkanen, L.; Laakso, M.; Pyorala, K. High plasma insulin level associated with coronary heart disease in the elderly. Am. J Epidemiol., 1993, 137, 1190-1202.
272. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352, 854-865.
273. Yki-Järvinen, H.; Esko, N.; Eero, H.; Taskinen, M-R. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am. J. Med., 1988, 84, 185-192.
274. Ihlemann, N.; Rask-Madsen, C.; Kober, L.; Torp-Pedersen, C. Vascular insulin response is preserved in non-diabetic patients with coronary artery disease, despite endothelial dysfunction. Scand. Cardiovasc. J., 2004, 38, 22-27.
275. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen K, Westerbacka J, Yki.Järvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 545-550.
276. Rask-Madsen, C.; Ihlemann, N.; Krarup, T.; Christiansen, E.; Kober, L.; Nervil Kistorp, C.; Torp-Pedersen, C. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes, 2001, 50, 2611-2618.
277. Gaenzer, H.; Neumayr, G.; Marschang, P.; Sturm, W.; Lechleitner, M.; Föger, B.; Kirchmair, R.; Patsch, J. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am. J. Cardiol., 2002, 89, 431-434.
278. Evans, M.; Anderson, R.; Smith, J.; Khan, N.; Graham, J.; Thomas, A.; Morris, K.; Deely, D.; Frenneaux, M.; Davies, J.; Rees, A. Effects of insulin lispro and chronic vitamin C therapy on post-prandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Eur. J. Clin, Invest., 2003, 33, 231-238.
279. Vehkavaara, S.; Yki-Järvinen, H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 325-330.
280. Makimattila, S.; Liu, M.L.; Vakkilainen, J.; Schlenzka, A.; Lahdenpera, S.; Syvanne, M.; Mantysaari, M.; Summanen, P.; Bergholm, R.; Taskinen, M-R.; Yki-Järvinen, H. Impaired endothelium-dependent vasodilation in NIDDM; relation to LDL size, oxidized LDL and antioxidants. Diabetes Care, 1999, 22, 973-981.
281. Malmberg, K.; Ryden, L.; Wedel, H.; Birkeland, K.; Bootsma, A.; Dickstein, K.; Efendic, S.; Fisher, M.; Hamsten, A.; Herlitz, J.; Hildebrandt, P.; MacLeod, K.; Laakso, M.; Torp-Pedersen, C.; Waldenstrom, A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DI-GAMI-2): effects on mortality and morbidity. Eur. Heart J., 2005, 26, 650-661.
282. Szymborska-Kajanek, A.; Strojek, K. Hypoglycaemic treatment in type 2 diabetic patients after myocardial infarction. Diabetes Res. Clin. Pract., 2006, 74 (Suppl), S30-S32.
283. Soran, H.; Barzangy, B.; Younis, N. The benefits of insulin therapy following acute myocardial infarction revised. Q. J. Med., 2006, 99, 635-637.
284. Cheung, N.W.; Wong, V.W.; McLean, M. The hyperglycemia: Intensive Insulin Infusion In Infarction (HI-5) Study. Diabetes Care, 2006, 29, 765-770.
285. Vanhorebeek, I.; Langouche, L.; Van den Berghe, G. Glycemic and nonglycemic effects of insulin: how did they contribute to a better outcome of critical illness?. Curr. Opin. Crit. Care, 2005, 11, 304-311.
286. Dandona, P.; Chaudhuri, A.; Ghanim, H.; Mohanty, P. Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin. Thorac. Cardiovasc. Surg., 2006, 18, 293-301.
287. Dandona, P.; Chaudhuri, A.; Ghanim, H.; Mohanty, P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am. J. Cardiol., 2007, 99(4A), 15B-26B.
288. Miettinen, H.; Lehto, S.; Salomaa, V.; Mahonen, M.; Niemela, M.; Haffner, S.M.; Pyorala, H.; Tuomilehto, J. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care, 1998, 21, 69-75.
289. Chyun, D.; Vaccarino, V.; Murillo, J.; Young, L.H.; Krumholz, H.M. Cardiac outcomes after myocardial infarction in elderly patients with diabetes mellitus. Am. J. Crit. Care, 2002, 11, 504-519.
290. Sundell, J.; Laine, H.; Nuutila, P.; Ronnemaa, T.; Luotolahti, M.; Raitakari, O.; Knuuti, J. The effects of insulin and short-term hyperglycaemia on myocardial blood flow in young men with uncomplicated type 1 diabetes. Diabetologia, 2002, 45, 775-782.
291. Antman, E.M.; Anbe, D.T.; Armstrong, P.W.; Bates, E.R.; Green, L.A,, Hand, M.; Hochman, J.S.; Krumholz, H.M.; Kushner, F.G.; Lamas, G.A.; Mullany, C.J.; Ornato, J.P.; Pearle, D.L.; Sloan, M.A.; Smith, S.C.; Antman, E.M.; Smith, S.C,, Alpert, J.S.; Anderson, J.L.; Faxon, D.P.; Fuster, V.; Gibbons, R.J.; Gregoratos, G.; Halperin, J.L.; Hiratzka, L.F.; Hunt, S.A.; Jacobs, A.K, Ornato, J.P. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation, 2004, 110, 588-636.
292. Van den Berghe, G. Insulin vs. strict blood glucose control to achieve a survival benefit after AMI? Eur. Heart J., 2005, 26, 639-641.
293. Stratton, I.M.; Adler A.I.; Neil, H.A.W.; Matthews D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C.; Holman, R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321, 405-412.
294. Hellman, R.; Regan, J.; Rosen, H. Effect of intensive treatment of diabetes on the risk of death or renal failure in NIDDM and IDDM. Diabetes Care, 1997, 20, 258-264.